Send us a text

🧪 Study:

Retrospective look at patients with intracranial hemorrhage (ICH) on warfarin for mechanical valves.

Followed for stroke, rebleed, mortality.

📈 Findings:

Only 2 strokes in first 7 days after stopping warfarin.

Most resumed warfarin around day 7 with low rebleed risk.

⚠️ Exclusions:

Massive bleeds, unstable patients, large hematomas may require longer delay.

🧩 Clinical Takeaway:

Restarting warfarin at 7 days appears safe in stable patients.

Still a team-based call — include cardiology, neurology, neurosurgery.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Myth:

“Delay levodopa to delay motor complications.”

🧪 LEAP Trial (Levodopa in Early Parkinson’s):

Compared early start vs 40-week delayed start.

5-year follow-up showed no difference in motor fluctuations or dyskinesia.

📈 Key Outcomes:

Early levodopa = better function earlier, no long-term harm.

Wearing off effect was similar in both groups.

🧩 Clinical Takeaway:

Don’t hold back levodopa if patient is symptomatic.

Starting early improves quality of life without hastening decline.

Personalize the approach — don’t delay just for dogma.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Question:

What's the optimal hemoglobin threshold for transfusion post-MI?

Old dogma: “Keep Hgb >10”.

New data: Less might be just as safe.

🧪 The MINT Trial (Myocardial Ischemia & Transfusion):

Compared liberal (Hgb <10) vs restrictive (Hgb <8) transfusion strategies.

Lower 30-day recurrent MI or cardiac death seen with Hgb ≥10 approach.

But... secondary analysis showed no major difference between 9 vs 10.

⚠️ Risks of Transfusion:

Volume overload (TACO).

Hemolytic and allergic reactions.

Cost and hospital stay increase.

🧩 Clinical Takeaway:

Consider transfusing at Hgb 9–10 in post-MI, particularly if symptoms or hemodynamics justify it.

Be cautious, but not rigid — individualize based on patient condition.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Context:

Blood pressure errors due to bad positioning = misdiagnosis and mistreatment.

We often blame the drug, when the data was flawed to begin with.

🧪 Study Highlights:

104 patients tested with 3 positions:

Hand in lap: BP falsely elevated by 4 mmHg.

Arm unsupported: +6 mmHg (most common real-world scenario).

Arm supported at heart level: accurate.

✅ Gold Standard Technique:

Seated, feet flat on floor, arm supported at heart level, relaxed.

No caffeine, nicotine, or exercise 30 minutes prior.

No talking. Cuff on bare skin, correct size (80% of upper arm).

Wait 5 minutes pre-reading. Repeat if >5 mmHg difference.

⚠️ Clinical Consequences:

Misclassified HTN → overtreatment, hypotension, dizziness.

Standardize BP checks in your clinic—“militant consistency” matters.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Context:

Episodic migraines (<15 days/month) that don’t respond to traditional preventives.

Patients often fail beta blockers, AEDs, TCAs, CCBs — need new options.

🧪 Study – RCT on Atogepant:

315 patients, mostly women, who failed ≥2 oral preventives.

Randomized to atogepant 60 mg daily vs placebo.

Follow-up: 3 months.

📈 Outcomes:

≥50% migraine reduction:

51% in atogepant group vs 18% placebo.

Most common side effect: Constipation (10% vs 3%).

💊 Mechanism:

CGRP receptor antagonist – blocks calcitonin gene-related peptide, a known migraine mediator.

🧩 Clinical Application:

Strong option for treatment-refractory episodic migraine.

Easier than injectables; potential for earlier use in future guidelines.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Context:

For patients who absolutely cannot tolerate statins — despite trying multiple options or experiencing severe side effects.

Reminder: Always try multiple statins first (different types, dosages, timing) before declaring “statin intolerance.”

💊 What is Bempedoic Acid?

Non-statin oral agent, works upstream of HMG-CoA reductase.

Liver-activated – avoids muscle toxicity seen in statins.

First oral non-statin to reduce MACE-4 endpoints.

📈 Clinical Impact:

LDL-C reduction: 20–25%.

Cardiovascular events:

23% ↓ in MI.

19% ↓ in coronary revascularization.

⚠️ Adverse Effects:

Gout, gallstones, elevated transaminases.

Avoid if history of uric acid disorders.

🧩 Clinical Takeaway:

Great adjunct to maximally tolerated statin or for rare, true statin-intolerant patients.

Not first-line — statins remain king, with 40–50% LDL reduction.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Context:

BBs have been MI standard since the thrombolysis era.

But do they still help when patients get PCI, statins, and ACEs?

🧪 Two Major Studies:

Swedish Registry Study:

Post-MI patients with preserved EF.

All received PCI + standard meds.

BB vs no BB: No difference in death or recurrent MI.

French Study (New England Journal):

MI 2.9 years prior, preserved EF.

BB continuation vs discontinuation:

Slight reduction in composite endpoint (death/MI/stroke/hospitalization).

Driven mostly by fewer hospitalizations (17% vs 19%).

⚖️ Pros and Cons of Beta Blockers:

✅ Pro: Cardioprotection, arrhythmia prevention.

❌ Con: Depression, fatigue, ED, bradycardia.

BBs aren’t benign — side effects matter to patients.

🧩 Clinical Pearls:

If EF is normal and patient is stable post-MI: Reassess need for long-term BB.

Ongoing trials will help guide “de-prescription” thresholds.

Don't forget individualized care: patient preference, arrhythmia risk, BP goals.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Context:

Nursing home residents are fragile fall-prone patients.

Starting a new antihypertensive could trigger orthostasis → serious fractures.

🧪 Study – VA Nursing Home Cohort:

13,000+ residents tracked from 2006–2019, mean age ~78.

Examined fracture risk 30 days after starting an antihypertensive.

Fractures studied: Pelvic, hip (requiring surgery), humerus, radius, ulna.

📈 Outcomes:

New antihypertensive initiated → 4.5 serious falls per 100 person-years.

No med change → 2.2 events per 100 person-years.

That’s >2x risk with a new med.

🩺 Clinical Tips:

Orthostatic BP check should be done 3–6 minutes after standing (not just 1–2 min).

Median best time: 4.5 minutes.

Use shared decision-making: Is the BP goal worth a possible hip fracture?

Consider deprescribing or "start low, go slow" approach in long-term care.

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Context:

Subclinical atrial fibrillation = asymptomatic episodes of AF detected by implantable monitors or Holters, lasting 6 minutes to 24 hours.

Big Question: Should we anticoagulate these patients?

🧪 Study Highlights – ARTESiA Trial:

Design: 4,012 patients (mean age 76.8), randomized to apixaban 5 mg BID vs ASA 81 mg daily.

Inclusion: Age >55 with or without history of stroke/TIA; device-confirmed subclinical AF.

📈 Outcomes:

Primary endpoint: Stroke or systemic embolism.

With prior stroke/TIA:

Apixaban significantly reduced events: 1.2% vs 3.4% annually.

Without prior stroke/TIA:

No significant difference: 0.74% (apixaban) vs 1.07% (ASA).

🧩 Clinical Pearls:

Don’t reflexively anticoagulate all device-detected AF — stratify by stroke history.

Consider CHA₂DS₂-VASc, but more importantly, patient-specific functional risk.

Use the Modified Rankin Scale to contextualize why stroke prevention matters:

0 = no symptoms, 5 = severe disability, 6 = death.

Patient framing tip: “If a stroke leaves you unable to walk, speak, or go to the bathroom independently, would that be worth preventing with a pill?”

Please visit www.Brilliantcourses.com to reflect on this activity with Learner+ platform to earn CME/CE.

Send us a text

🧠 Clinical Context:

Subclinical atrial fibrillation = asymptomatic episodes of AF detected by implantable monitors or Holters, lasting 6 minutes to 24 hours.

Big Question: Should we anticoagulate these patients?

🧪 Study Highlights – ARTESiA Trial:

Design: 4,012 patients (mean age 76.8), randomized to apixaban 5 mg BID vs ASA 81 mg daily.

Inclusion: Age >55 with or without history of stroke/TIA; device-confirmed subclinical AF.

📈 Outcomes:

Primary endpoint: Stroke or systemic embolism.

With prior stroke/TIA:

Apixaban significantly reduced events: 1.2% vs 3.4% annually.

Without prior stroke/TIA:

No significant difference: 0.74% (apixaban) vs 1.07% (ASA).

🧩 Clinical Pearls:

Don’t reflexively anticoagulate all device-detected AF — stratify by stroke history.

Consider CHA₂DS₂-VASc, but more importantly, patient-specific functional risk.

Use the Modified Rankin Scale to contextualize why stroke prevention matters:

0 = no symptoms, 5 = severe disability, 6 = death.

Patient framing tip: “If a stroke leaves you unable to walk, speak, or go to the bathroom independently, would that be worth preventing with a pill?”

Thanks for listening! Stay ahead with the latest in clinical medicine, board prep, and earn CME credits.

Visit www.brilliantcourses.com to learn more and claim credits for this educational activity. 

Stay informed, stay prepared—see you next time!